Shares Magazine
377.67p-3.83 (-1.00%)02 Oct 2024, 12:34
Jump to:
Oxford Biomedica PLC Fundamentals
| Company Name | Oxford Biomedica PLC | Last Updated | 2024-10-02 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 105.340 m | Market Cap | £397.83 m |
| PE Ratio | 20.62 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£1.63 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.4503 | Debt Equity Ratio | 1.5921 |
| Asset Equity Ratio | 3.4396 | Cash Equity Ratio | 1.1431 |
| Quick Ratio | 1.8353 | Current Ratio | 2.35 |
| Price To Book Value | 6.0680 | ROCE | 0 |
Oxford Biomedica PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Oxford Biomedica PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £75.69 m | £133.78 m | £69.73 m |
| Intangible Assets | £30.98 m | £105.89 m | £52,000.00 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £111.01 m | £244.68 m | £73.39 m |
| Stocks | £12.87 m | £12.63 m | £9.52 m |
| Debtors | £15.42 m | £49.86 m | £36.31 m |
| Cash & Equivalents | £103.72 m | £141.28 m | £109.02 m |
| Other Assets | £4.34 m | £5.01 m | £3.60 m |
| Total Assets | £252.34 m | £460.18 m | £237.23 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £44.31 m | £59.66 m | £33.31 m |
| Creditors after 1 year | £130.19 m | £164.32 m | £16.58 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £174.51 m | £223.99 m | £49.89 m |
| Net assets | £77.83 m | £236.19 m | £187.34 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £48.40 m | £48.13 m | £43.09 m |
| Share Premium | £380.33 m | £379.95 m | £307.76 m |
| Profit / Loss | -£188.53 m | -£45.98 m | £19.88 m |
| Other Equity | £74.01 m | £204.65 m | £187.34 m |
| Preference & Minorities | £3.83 m | £31.54 m | 0 |
| Total Capital Employed | £77.83 m | £236.19 m | £187.34 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | £0.59 | £0.35 | £0.04 |
| Debt-to-Equity | £1.46 | £0.54 | £0.05 |
| Assets / Equity | 3.4396 | 3.4396 | 3.4396 |
| Cash / Equity | 1.1431 | 1.1431 | 1.1431 |
| EPS | -£0.63 | -£0.41 | £0.23 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£28.52 m | -£12.62 m | £25.45 m |
| Cashflow before financing | -£41.22 m | £86.01 m | £71.66 m |
| Increase in Cash | -£38.41 m | £29.55 m | £62.20 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £89.54 m | £139.99 m | £142.80 m |
| Cost of sales | £49.81 m | £70.81 m | £60.16 m |
| Gross Profit | £39.73 m | £69.18 m | £82.64 m |
| Operating Profit | -£184.17 m | -£30.22 m | £20.77 m |
| Pre-Tax profit | -£188.53 m | -£45.98 m | £19.88 m |
Oxford Biomedica PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe. |
| Latest Interim Date | 23 Sep 2024 |
| Latest Fiscal Year End Date | 29 Apr 2024 |
Oxford Biomedica PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2012-04-30 | Mr. Andrew Brian Wood | Executive Director,Chief Financial Officer and Company Sec |
| 2020-06-23 | Dr. Lorenzo Tallarigo, M.D. | Non-Executive Director,Chairman |
| 2016-01-05 | Mr. Daniel B. Soland | Non-Executive Director |
| 2024-04-30 | Ms. Leone D Patterson | Non-Executive Director |
| 2013-06-06 | Dr. Stuart Naylor, PhD | Executive Director,Chief Scientific Officer |
| 2022-05-27 | Mr. John Andrew Dawson CBE | Executive Director,Chief Executive Officer |
| 2011-01-10 | Dr. Alexander D Lewis | Non-Executive Director |
| 2022-04-27 | Dr. Andrew John William Heath | Non-Executive Director |
| 2020-06-08 | Professor Alan John Kingsman | Non-Executive Director,Chairman |
| 2017-04-28 | Dr. Paul Blake | Executive Director,Chief Development Officer |
| 2018-06-29 | Mr. Peter J Nolan | Executive Director,Chief Business Officer |
| 2016-04-30 | Mr. Philip Nicholas Rodgers | Non-Executive Director |
| 2011-08-09 | Mr. Nick Woolf | Investor Relation |
| 2011-08-09 | Dr. Michael McDonald | Executive Director,Chief Executive Officer |
| 2024-04-30 | Dr. Roch F. Doliveux | Non-Executive Director,Chairman |
| 2024-06-21 | Dr. Michael Hayden | Non-Executive Director |
| 2011-08-09 | Dr. Peter Johnson BSc,PhD,FRSC,FIBiol,FRCPath | Non-Executive Director,Chairman |
| 2011-08-09 | Professor Susan Mary Kingsman, M.A.,PhD | Executive Director |
| 2018-04-26 | Mr. Timothy William Watts | Non-Executive Director |
| 2021-02-03 | Mr. Martin Henry Diggle | Non-Executive Director |
| 2024-04-30 | Dr. Frank Mathias | Executive Director,Chief Executive Officer |
| 2024-04-30 | Dr. Heather Elizabeth Preston, M.D. | Non-Executive Director |
| 2024-04-30 | Mr. Stuart Henderson | Non-Executive Director,Vice Chairman |
| 2024-09-02 | Mr. Stuart Paynter | Executive Director,Chief Financial Officer |
| 2024-06-21 | Ms. Catherine Moukheibir | Non-Executive Director |
| 2024-04-30 | Dr. Siyamak Rasty | Non-Executive Director |
| 2024-04-30 | Professor Dame Kay Davies | Non-Executive Director,Senior Independent Director |
| 2024-04-30 | Ms. Namrata P Patel | Non-Executive Director |
Oxford Biomedica PLC Contact Details
| Company Name | Oxford BioMedica PLC |
|---|---|
| Address | Windrush Court, Transport Way, Oxford, OX4 6LT |
| Telephone | +44 1865783000 |
| Website | https://www.oxb.com |
Oxford Biomedica PLC Advisors
| Stockbroker | WG Partners |
|---|
| Financial Adviser | Peel Hunt LLP |
|---|---|
| Phone | +44 2074188900 |
| Stockbroker | Peel Hunt LLP |
|---|---|
| Phone | +44 2074188900 |
| Remuneration Consultant | Deloitte LLP |
|---|---|
| Phone | +44 2079363000 |
| Fax | +44 2075831198 |
| Financial Adviser | WG Partners LLP |
|---|
| Financial PR Adviser | Consilium Strategic Communications |
|---|---|
| Phone | +44 2037095700 |
| Bank | Barclays Bank PLC |
|---|
| Registrar | Link Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
| Solicitor | Covington & Burling LLP |
|---|---|
| Phone | +44 2070672000 |
| Fax | +44 2070672222 |
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Fidelity China Special Situations PLC | 239.12 | 6.99 |
| Ithaca Energy PLC | 112.40 | 4.46 |
| Prudential PLC | 716.00 | 3.53 |
| Harbour Energy PLC | 279.20 | 2.91 |
| Schroder Asiapacific Fund PLC | 561.00 | 2.56 |
| BP PLC | 411.10 | 2.52 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Wizz Air Holdings PLC | 1,283.95 | -6.08 |
| Aston Martin Lagonda Global Holdings PLC | 110.34 | -5.85 |
| Jd Sports Fashion PLC | 141.63 | -5.27 |
| Close Brothers Group PLC | 385.00 | -4.37 |
| Ocado Group PLC | 380.80 | -3.40 |
| Severn Trent PLC | 2,603.00 | -3.23 |